Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
复制标题
DOI：
10.1054/bjoc.2000.1142
复制
发表时间：
2000-06-01
影响因子：
8.8
通讯作者：
Fallowfield, L
中科院分区：
文献类型：
--
作者：
Jenkins, V;Fallowfield, L
本文报告了地区综合医院和大学医院临床医生进行讨论后患者同意或拒绝参加癌症随机试验的原因。 204 名患者在咨询后填写了一份包含 16 项的调查问卷，其中 112 名（55%）是患有乳腺癌的女性。总体结果显示，147 名 (72.1%) 患者接受参加随机临床试验 (RCT)。提名参加试验的主要原因是“其他人会受益”（23.1%）和“信任医生”（21.1%）。拒绝参加试验的主要原因之一是患者“担心随机化”（19.6%）。与不接受治疗的试验 46 (60.5%) 相比，每组 98 提供积极治疗的试验的接受率显着较高 (80.6%)，chi(2) 检验 P = 0.003。该研究概述了许多似乎影响患者决定接受或拒绝参加癌症治疗随机对照试验的因素。一个重要因素是试验是否在所有研究组中提供积极治疗。促进对医生的信任和信心的沟通也是一种强大的激励影响。 (C) 2000 年癌症研究运动。
This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that 'others will benefit' (23.1%) and 'trust in the doctor' (21.1%). One of the main reasons for declining trial entry was that patients were 'worried about randomization' (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), chi(2) test P = 0.003. The study outlines a number of factors that appear to influence a patient's decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence. (C) 2000 Cancer Research Campaign.